Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2013-002132-25Phase 2Active
Phase 2, randomised, open-label trial of ruxolitinib in polycythemia vera (PV) and thrombocythemia (2 arms), sponsored by University Hospital RWTH Aachen. Primary endpoint: Complete clinicohematologic response rate at month 6. Started Feb 2015; status: active.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on 2013-002132-25.